Non-steroidal anti-inflammatory drugs use in older adults decreases risk of Alzheimer’s disease mortality


Autoři: Julián Benito-León aff001;  Israel Contador aff004;  Saturio Vega aff005;  Alberto Villarejo-Galende aff001;  Félix Bermejo-Pareja aff003
Působiště autorů: Department of Neurology, University Hospital “12 de Octubre”, Madrid, Spain aff001;  Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain aff002;  Department of Medicine, Complutense University, Madrid, Spain aff003;  Department of Basic Psychology, Psychobiology and Methodology of Behavioural Sciences, University of Salamanca, Salamanca, Spain aff004;  Arévalo Health Center, Arévalo, Ávila, Spain aff005;  Clinical Research Unit (I+12), University Hospital “12 de Octubre”, Madrid, Spain aff006
Vyšlo v časopise: PLoS ONE 14(9)
Kategorie: Research Article
doi: 10.1371/journal.pone.0222505

Souhrn

Alzheimer disease (AD) mortality risk in a large cohort of subjects treated or not with non-steroidal anti-inflammatory drugs (NSAIDs) is unknown. Our objective was to determine whether NSAIDs use is associated with decreased risk of AD mortality. In this prospective, population-based study (Neurological Disorders in Central Spain [NEDICES]) of 5,072 people without AD (aged 65 years and older), sociodemographic, comorbidity factors, and current medications were recorded at baseline. Community-dwelling older adults were followed for a median of 12.7 years, after which the death certificates of deceased participants were examined. 2,672 (52.7%) of 5,072 participants died, including 504 (18.9%) NSAIDs users and 2,168 (81.1%) non-users. Of the 2,672 deceased participants, 113 (4.2%) had AD as a cause of death (8 [1.6%] among NSAIDs users and 105 [4.8%] among non-users, chi-square = 10.70, p = 0.001). In an unadjusted Cox model, risk of AD mortality was decreased in NSAIDs users (hazard ratio [HR] for AD mortality = 0.35, 95% confidence interval [CI] 0.17–0.72, p = 0.004) when compared to non-users. After adjusting for numerous demographic factors and co-morbidities, the HR for AD mortality in NSAIDs users was 0.29, 95% CI 0.12–0.73, p = 0.009. Stratified analyses showed a significantly decreased risk of AD mortality with aspirin, whereas non-aspirin NSAIDs only showed a statistical trend toward significance in the adjusted Cox regression models. NSAIDs use was associated with 71% decreased risk of AD mortality in older adults. Our results support the hypothesis that NSAIDs use is a protective factor of developing AD.

Klíčová slova:

Medicine and health sciences – Pharmacology – Drugs – Analgesics – NSAIDs – Pain management – Mental health and psychiatry – Dementia – Alzheimer's disease – Neurology – Neurodegenerative diseases – Cognitive neurology – Cerebrovascular diseases – Vascular medicine – Blood pressure – Hypertension – Primary hypertension – Secondary hypertension – Biology and life sciences – Neuroscience – Cognitive science – Cognitive neuroscience – Social sciences – Sociology – Education – Educational attainment


Zdroje

1. Ali MM, Ghouri RG, Ans AH, Akbar A, Toheed A. Recommendations for Anti-inflammatory Treatments in Alzheimer's Disease: A Comprehensive Review of the Literature. Cureus. 2019;11(5):e4620. Epub 2019/07/18. doi: 10.7759/cureus.4620 31312547; PubMed Central PMCID: PMC6615583.

2. McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet (London, England). 1990;335(8696):1037. Epub 1990/04/28. doi: 10.1016/0140-6736(90)91101-f 1970087.

3. Wang J, Tan L, Wang HF, Tan CC, Meng XF, Wang C, et al. Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis. Journal of Alzheimer's disease: JAD. 2015;44(2):385–96. doi: 10.3233/JAD-141506 25227314.

4. Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev. 2012;(2):CD006378. doi: 10.1002/14651858.CD006378.pub2 22336816.

5. Meyer PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan ME, Savard M, et al. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology. 2019;92(18):e2070–e80. Epub 2019/04/07. doi: 10.1212/WNL.0000000000007232 PubMed Central PMCID: PMC6512884. 30952794

6. Nevado-Holgado AJ, Lovestone S. Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach. Comput Struct Biotechnol J. 2017;15:1–7. doi: 10.1016/j.csbj.2016.10.003 27872687; PubMed Central PMCID: PMC5109283.

7. Sanz-Blasco S, Calvo-Rodríguez M, Caballero E, García-Durillo M, Nuñez L, Villalobos C. Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake. Curr Alzheimer Res. 2018;15(6):504–10. doi: 10.2174/1567205015666171227154016 29283047.

8. Hoyer S. Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease. Acta neurologica Scandinavica Supplementum. 1996;165:18–24. 8740985.

9. Benito-León J, Louis ED, Villarejo-Galende A, Labiano-Fontcuberta A, Bermejo-Pareja F. Self-rated health and risk of incident essential tremor: A prospective, population-based study (NEDICES). Parkinsonism Relat Disord. 2015;21(6):622–8. Epub 2015/04/19. doi: 10.1016/j.parkreldis.2015.03.023 25887487.

10. Zhang C, Wang Y, Wang D, Zhang J, Zhang F. NSAID Exposure and Risk of Alzheimer's Disease: An Updated Meta-Analysis From Cohort Studies. Frontiers in Aging Neuroscience. 2018;10(83). doi: 10.3389/fnagi.2018.00083 29643804

11. Varga Z, Sabzwari SRA, Vargova V. Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue. Cureus. 2017;9(4):e1144. doi: 10.7759/cureus.1144 28491485; PubMed Central PMCID: PMC5422108.

12. Bermejo-Pareja F, Benito-León J, Louis ED, Trincado R, Carro E, Villarejo A, et al. Risk of incident dementia in drug-untreated arterial hypertension: a population-based study. Journal of Alzheimer's disease: JAD. 2010;22(3):949–58. Epub 2010/09/23. doi: 10.3233/JAD-2010-101110 20858957.

13. Benito-León J, Bermejo-Pareja F, Morales JM, Vega S, Molina JA. Prevalence of essential tremor in three elderly populations of central Spain. Mov Disord. 2003;18(4):389–94. Epub 2003/04/03. doi: 10.1002/mds.10376 12671944.

14. Benito-León J, Bermejo-Pareja F, Rodriguez J, Molina JA, Gabriel R, Morales JM, et al. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord. 2003;18(3):267–74. Epub 2003/03/07. doi: 10.1002/mds.10362 12621629.

15. Benito-León J, Bermejo-Pareja F, Morales-González JM, Porta-Etessam J, Trincado R, Vega S, et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology. 2004;62(5):734–41. Epub 2004/03/10. doi: 10.1212/01.wnl.0000113727.73153.68 15007123.

16. Díaz-Guzmán J, Bermejo-Pareja F, Benito-León J, Vega S, Gabriel R, Medrano MJ, et al. Prevalence of stroke and transient ischemic attack in three elderly populations of central Spain. Neuroepidemiology. 2008;30(4):247–53. Epub 2008/06/03. doi: 10.1159/000135643 18515974.

17. Bermejo-Pareja F, Benito-León J, Vega S, Olazarán J, de Toledo M, Díaz-Guzmán J, et al. Consistency of clinical diagnosis of dementia in NEDICES: A population-based longitudinal study in Spain. J Geriatr Psychiatry Neurol. 2009;22(4):246–55. Epub 2009/05/07. doi: 10.1177/0891988709335794 19417217.

18. Bermejo-Pareja F, Benito-León J, Vega S, Medrano MJ, Roman GC, Neurological Disorders in Central Spain Study G. Incidence and subtypes of dementia in three elderly populations of central Spain. J Neurol Sci. 2008;264(1–2):63–72. Epub 2007/08/31. doi: 10.1016/j.jns.2007.07.021 17727890.

19. Morales JM, Bermejo FP, Benito-León J, Rivera-Navarro J, Trincado R, Gabriel SR, et al. Methods and demographic findings of the baseline survey of the NEDICES cohort: a door-to-door survey of neurological disorders in three communities from Central Spain. Public Health. 2004;118(6):426–33. doi: 10.1016/j.puhe.2003.10.007 15313596

20. Bermejo-Pareja F, Benito-León J, Vega QS, Díaz-Guzmán J, Rivera-Navarro J, Molina JA, et al. [The NEDICES cohort of the elderly. Methodology and main neurological findings]. Rev Neurol. 2008;46(7):416–23. Epub 2008/04/05. 18389461.

21. Vega S, Benito-León J, Bermejo-Pareja F, Medrano MJ, Vega-Valderrama LM, Rodríguez C, et al. Several factors influenced attrition in a population-based elderly cohort: neurological disorders in Central Spain Study. J Clin Epidemiol. 2010;63(2):215–22. Epub 2009/05/29. doi: 10.1016/j.jclinepi.2009.03.005 19473811.

22. Benito-León J, Contador I, Louis ED, Cosentino S, Bermejo-Pareja F. Education and risk of incident dementia during the premotor and motor phases of essential tremor (NEDICES). Medicine (Baltimore). 2016;95(33):e4607. doi: 10.1097/MD.0000000000004607 27537597.

23. Benito-León J, Romero JP, Louis ED, Bermejo-Pareja F. Faster cognitive decline in elders without dementia and decreased risk of cancer mortality: NEDICES Study. Neurology. 2014;82(16):1441–8. Epub 2014/04/11. doi: 10.1212/WNL.0000000000000350 24719490; PubMed Central PMCID: PMC4001199.

24. Benito-León J, Louis ED, Bermejo-Pareja F, Neurological Disorders in Central Spain Study G. Population-based case-control study of cognitive function in essential tremor. Neurology. 2006;66(1):69–74. Epub 2006/01/13. doi: 10.1212/01.wnl.0000192393.05850.ec 16401849.

25. Benito-León J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. Journal of Alzheimer's disease: JAD. 2010;21(1):95–102. Epub 2010/04/24. doi: 10.3233/JAD-2010-100180 20413854.

26. Benito-León J, Mitchell AJ, Vega S, Bermejo-Pareja F. A population-based study of cognitive function in older people with subjective memory complaints. Journal of Alzheimer's disease: JAD. 2010;22(1):159–70. doi: 10.3233/JAD-2010-100972 20847410

27. Benito-León J, Louis ED, Sánchez-Ferro A, Bermejo-Pareja F. Rate of cognitive decline during the premotor phase of essential tremor: a prospective study. Neurology. 2013;81(1):60–6. Epub 2013/05/24. doi: 10.1212/WNL.0b013e318297ef2b 23700331; PubMed Central PMCID: PMC3770204.

28. Louis ED, Benito-León J, Vega-Quiroga S, Bermejo-Pareja F, Neurological Disorders in Central Spain Study G. Cognitive and motor functional activity in non-demented community-dwelling essential tremor cases. J Neurol Neurosurg Psychiatry. 2010;81(9):997–1001. Epub 2010/06/16. doi: 10.1136/jnnp.2009.202838 20547612.

29. American Psychiatric A. Diagnostic and Statistical Manual of Mental Disorders DSM-IV. Washington1994 1994.

30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–44. doi: 10.1212/wnl.34.7.939 6610841

31. Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, et al. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain. 2008;131(Pt 3):651–64. Epub 2008/02/23. doi: 10.1093/brain/awn008 18292081; PubMed Central PMCID: PMC2628581.

32. Choi SH, Bosetti F. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging. 2009;1(2):234–44. Epub 2010/02/17. doi: 10.18632/aging.100021 20157512; PubMed Central PMCID: PMC2806008.

33. Woodling NS, Andreasson KI. Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease. ACS Chem Neurosci. 2016;7(4):454–63. Epub 2016/03/17. doi: 10.1021/acschemneuro.6b00016 26979823; PubMed Central PMCID: PMC5239037.

34. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet (London, England). 2006;367(9510):606–17. doi: 10.1016/S0140-6736(06)68040-9 16488805.

35. Choi SH, Aid S, Caracciolo L, Minami SS, Niikura T, Matsuoka Y, et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. Journal of neurochemistry. 2013;124(1):59–68. Epub 2012/10/23. doi: 10.1111/jnc.12059 23083210; PubMed Central PMCID: PMC3780364.

36. Prestia A, Caroli A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology. 2013;80(11):1048–56. doi: 10.1212/WNL.0b013e3182872830 23390179.

37. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Archives of general psychiatry. 2012;69(1):98–106. Epub 2012/01/04. doi: 10.1001/archgenpsychiatry.2011.155 22213792.

38. Imbimbo BP. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. Expert Opin Investig Drugs. 2009;18(8):1147–68. doi: 10.1517/13543780903066780 19589092.

39. McGeer PL, Guo JP, Lee M, Kennedy K, McGeer EG. Alzheimer's Disease Can Be Spared by Nonsteroidal Anti-Inflammatory Drugs. Journal of Alzheimer's disease: JAD. 2018;62(3):1219–22. Epub 2017/11/06. doi: 10.3233/JAD-170706 29103042; PubMed Central PMCID: PMC5870017.

40. Romero JP, Benito-León J, Louis ED, Pareja FB. Under Reporting of Dementia Deaths on Death Certificates: A Systematic Review of Population-based Cohort Studies. J Alzheimers Dis. 2014. Epub 2014/03/04. doi: 10.3233/JAD-132765 24583403.


Článek vyšel v časopise

PLOS One


2019 Číslo 9

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Výhody léčby pacientů s DM 2. typu GLP-1 agonisty
nový kurz
Autoři: prof. MUDr. Martin Haluzík, DrSc.

Syndrom suchého oka – diagnostika, komplikace a léčba
Autoři: MUDr. Petr Výborný, CSc., FEBO

Systémová léčba psoriázy
Autoři: MUDr. Jiří Horažďovský, Ph.D

Klinická farmakokinetika betablokátorů
Autoři:

Současné možnosti terapie osteoartrózy
Autoři: MUDr. Jakub Holešovský

Všechny kurzy
Kurzy Doporučená témata